ATG is anti-thymocyte globulin, the principle of this drug for the treatment of aplastic anemia is mainly to kill immune T cells.
The principle of anti-thymocyte globulin in the treatment of aplastic anemia is to kill immune T cells through complement- and antibody-dependent cell-mediated cytotoxicity, and to induce apoptosis of T cells, block their signaling, make T cells inactive, and thus inhibit the phagocytosis of T cells, so as to treat aplastic anemia.
It is contraindicated in people who are allergic to this drug, hypersensitive and have acute infections. Adverse reactions to this drug include tachycardia, peripheral thrombophlebitis, dizziness, weakness, nausea, vomiting, and dyspnea.
The above drugs should be applied under the supervision of a doctor and avoid self-medication to avoid adverse effects.